These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27827561)

  • 1. A Novel PEGylation Method for Improving the Pharmacokinetic Properties of Anti-Interleukin-17A RNA Aptamers.
    Haruta K; Otaki N; Nagamine M; Kayo T; Sasaki A; Hiramoto S; Takahashi M; Hota K; Sato H; Yamazaki H
    Nucleic Acid Ther; 2017 Feb; 27(1):36-44. PubMed ID: 27827561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of anti-interleukin-17A aptamer: suppression of interleukin-17A signaling and attenuation of autoimmunity in two mouse models.
    Ishiguro A; Akiyama T; Adachi H; Inoue J; Nakamura Y
    Arthritis Rheum; 2011 Feb; 63(2):455-66. PubMed ID: 20967861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production, purification and biological characterization of mono-PEGylated anti-IL-17A antibody fragments.
    Koussoroplis SJ; Heywood S; Uyttenhove C; Barilly C; Van Snick J; Vanbever R
    Int J Pharm; 2013 Sep; 454(1):107-15. PubMed ID: 23850622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonistic RNA aptamer specific to a heterodimeric form of human interleukin-17A/F.
    Adachi H; Ishiguro A; Hamada M; Sakota E; Asai K; Nakamura Y
    Biochimie; 2011 Jul; 93(7):1081-8. PubMed ID: 21524680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers.
    Moreno A; Pitoc GA; Ganson NJ; Layzer JM; Hershfield MS; Tarantal AF; Sullenger BA
    Cell Chem Biol; 2019 May; 26(5):634-644.e3. PubMed ID: 30827937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEGylation and biodistribution of an anti-MUC1 aptamer in MCF-7 tumor-bearing mice.
    Da Pieve C; Blackshaw E; Missailidis S; Perkins AC
    Bioconjug Chem; 2012 Jul; 23(7):1377-81. PubMed ID: 22708500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fate of PEGylated antibody fragments following delivery to the lungs: Influence of delivery site, PEG size and lung inflammation.
    Patil HP; Freches D; Karmani L; Duncan GA; Ucakar B; Suk JS; Hanes J; Gallez B; Vanbever R
    J Control Release; 2018 Feb; 272():62-71. PubMed ID: 29247664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab' antibody fragment after pulmonary delivery in three different species.
    Freches D; Patil HP; Machado Franco M; Uyttenhove C; Heywood S; Vanbever R
    Int J Pharm; 2017 Apr; 521(1-2):120-129. PubMed ID: 28192159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection and characterization of a new human Interleukin-17A blocking DNA aptamer using protein-SELEX.
    Shobeiri SS; Mashayekhi K; Khorrami M; Moghadam M; Sankian M
    Biochem Biophys Res Commun; 2022 Dec; 637():32-39. PubMed ID: 36375248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEGylation of interleukin-10 improves the pharmacokinetic profile and enhances the antifibrotic effectivity in CCl₄-induced fibrogenesis in mice.
    Mattos A; de Jager-Krikken A; de Haan M; Beljaars L; Poelstra K
    J Control Release; 2012 Aug; 162(1):84-91. PubMed ID: 22659050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PEGylation improves pharmacokinetic profile, liver uptake and efficacy of Interferon gamma in liver fibrosis.
    Bansal R; Post E; Proost JH; de Jager-Krikken A; Poelstra K; Prakash J
    J Control Release; 2011 Sep; 154(3):233-40. PubMed ID: 21664391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Properties of DNA Aptamers with Base Modifications.
    Gupta S; Drolet DW; Wolk SK; Waugh SM; Rohloff JC; Carter JD; Mayfield WS; Otis MR; Fowler CR; Suzuki T; Hirota M; Ishikawa Y; Schneider DJ; Janjic N
    Nucleic Acid Ther; 2017 Dec; 27(6):345-353. PubMed ID: 28961063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of PEGylation and immune complex formation on the pharmacokinetics and biodistribution of recombinant interleukin 10 in mice.
    Alvarez HM; So OY; Hsieh S; Shinsky-Bjorde N; Ma H; Song Y; Pang Y; Marian M; Escandón E
    Drug Metab Dispos; 2012 Feb; 40(2):360-73. PubMed ID: 22083830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract.
    Koussoroplis SJ; Paulissen G; Tyteca D; Goldansaz H; Todoroff J; Barilly C; Uyttenhove C; Van Snick J; Cataldo D; Vanbever R
    J Control Release; 2014 Aug; 187():91-100. PubMed ID: 24845126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, pharmacodynamics and safety of aptamers.
    Kovacevic KD; Gilbert JC; Jilma B
    Adv Drug Deliv Rev; 2018 Sep; 134():36-50. PubMed ID: 30321620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging PEGylated non-biologic drugs.
    Park EJ; Choi J; Lee KC; Na DH
    Expert Opin Emerg Drugs; 2019 Jun; 24(2):107-119. PubMed ID: 30957581
    [No Abstract]   [Full Text] [Related]  

  • 17. Modification of thiol functionalized aptamers by conjugation of synthetic polymers.
    Da Pieve C; Williams P; Haddleton DM; Palmer RM; Missailidis S
    Bioconjug Chem; 2010 Jan; 21(1):169-74. PubMed ID: 20000459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAID3--An interleukin-6 receptor-binding aptamer with post-selective modification-resistant affinity.
    Mittelberger F; Meyer C; Waetzig GH; Zacharias M; Valentini E; Svergun DI; Berg K; Lorenzen I; Grötzinger J; Rose-John S; Hahn U
    RNA Biol; 2015; 12(9):1043-53. PubMed ID: 26383776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor.
    Gupta S; Hirota M; Waugh SM; Murakami I; Suzuki T; Muraguchi M; Shibamori M; Ishikawa Y; Jarvis TC; Carter JD; Zhang C; Gawande B; Vrkljan M; Janjic N; Schneider DJ
    J Biol Chem; 2014 Mar; 289(12):8706-19. PubMed ID: 24415766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo.
    Ranganath S; Bhandari A; Avitahl-Curtis N; McMahon J; Wachtel D; Zhang J; Leitheiser C; Bernier SG; Liu G; Tran TT; Celino H; Tobin J; Jung J; Zhao H; Glen KE; Graul C; Griffin A; Schairer WC; Higgins C; Reza TL; Mowe E; Rivers S; Scott S; Monreal A; Shea C; Bourne G; Coons C; Smith A; Tang K; Mandyam RA; Masferrer J; Liu D; Patel DV; Fretzen A; Murphy CA; Milne GT; Smythe ML; Carlson KE
    PLoS One; 2015; 10(11):e0141330. PubMed ID: 26555695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.